MorphoSys Announces Clinical Milestone
(Thomson Reuters ONE) -
MorphoSys AG / MorphoSys Announces Clinical Milestone processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
First of up to Six Expected Clinical Phase 1 Milestones During 2010
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it
will receive a clinical milestone payment from Centocor Ortho Biotech Inc.
(formerly known as: Centocor, Inc.) in connection with the initiation of a phase
1 clinical trial of a HuCAL-derived antibody in the therapeutic area of
inflammatory and autoimmune diseases. The target against which the antibody is
directed is undisclosed.
As part of the Centocor Ortho Biotech Inc. collaboration in 2007, a HuCAL
antibody became the first from MorphoSys to be developed in two different
therapeutic areas - oncology and immunology and in 2009, a different HuCAL
antibody advanced in the therapeutic area of inflammation into a phase 1 trial.
Today's announcement marks the start of a fourth clinical trial that will be
running HuCAL antibodies. Further pre-clinical programs are ongoing.
"Our clinical pipeline is progressing very well, and we expect significant
progress in this regard during the course of 2010 with up to six new partnered
programs advancing into the clinic," commented Dr. Marlies Sproll, Chief
Scientific Officer of MorphoSys AG. "We are delighted to see another antibody
program advance into phase 1 clinical trials."
MorphoSys projects that in 2010 between four and six partnered programs could
enter clinical trials. Today's news represents the first HuCAL-derived antibody
to achieve this stage during the course of the year. By the end of this year, up
to 14 proprietary and partnered antibody programs are expected to be in clinical
trials including at least four programs in phase 2 clinical trials.
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients.
Via its business unit AbD Serotec, MorphoSys is expanding the reach of its
technologies in the diagnostics and research markets. MorphoSys is headquartered
in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol
"MOR". For further information, visithttp://www.morphosys.com/
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®) and RapMAT(®) are
registered trademarks of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
[HUG#1425803]
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,Prime All Share,CDAX,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press Release: http://hugin.info/130295/R/1425803/373992.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: MorphoSys AG via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 22.06.2010 - 07:31 Uhr
Sprache: Deutsch
News-ID 22781
Anzahl Zeichen: 0
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 217 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Announces Clinical Milestone"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
